<DOC>
	<DOCNO>NCT02425644</DOCNO>
	<brief_summary>International clinical trial compare ponesimod teriflunomide relapse multiple sclerosis</brief_summary>
	<brief_title>Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Male female subject age 18 55 year establish diagnosis MS McDonald 2010 relapse course onset ( i.e. , RRMS SPMS superimpose relapse ) . Subjects must active disease evidence one MS attack onset within period 12 1 month prior randomization , two MS attack onset within 24 1 month prior randomization , one gadoliniumenhancing ( Gd+ ) lesion ( ) brain MRI perform within 6 month prior randomization . Enrolled subject must ambulatory ( EDSS score 5.5 inclusive ) may treatmentna√Øve previously treat MS disease modify therapy . Subjects significant medical condition therapy condition ( e.g. , cardiovascular , pulmonary , immunological , hepatic , ophthalmological condition ) lactate pregnant woman eligible enter study . Subjects contraindication MRI clinically relevant medical surgical condition , opinion investigator , would put subject risk participate study eligible enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapse multiple sclerosis</keyword>
</DOC>